Austrian Institute of Technology, Austria
Selma Gogalic hascompletedher master of science and engineeringat the age of 23 years. In january 2013 she started her PhD at the Universityof Vienna/AustrianInstitute of Technologyon “multimodularbiomarkeranalysisworkflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer”. Part of this work hasbeenpublished in peerreviewedjournals. Currentlysheisalsolecturerat the University of AppliedSciencesin St.Pölten (Digital Healthcare) for measuring- and analyticalmethods in healthcaresystems.
Cancer of the bladder (BCa) is killing thousands of people a year. It is the fourth leading cause of cancer in men (US) and the costs for treatment are rising due to high relapse rate (50% within 2 years). To intervene recurrence of BCa routine cytology and cystoscopy are done, representing the gold standard. Nevertheless these diagnostic tools are expensive, time consuming, invasive and lead to urinary infections in up to 16% of patients. Therefore detection in urine to monitor recurrent BCa is in focus. Commercial urine based tests measure single markers, such asNMP-22 and BTA. However, none of them has proofed good sensitivity and specificity. To overcome the problem of low sensitivity and specificity we have developed a protein microarray based on a unique panel of 10 biomarkers. This BCa chip consists of ARChip Epoxyglass-slidesspotted with captureantibodies to bindthe respective biomarkers. The binding is then detected with a secondary biotinylated antibody and Dy647-streptavidin (simultaneouslywithin5hrs). The chip was validated using samples of 76 patients. ROC curves were generated and the optimal cut-off value determined. Expression of fourbiomarkers(DCN, VEGF, IL-8, EN-2) out of 10wassignificantlydifferentbetweenpatientsamples with recurrent and non-recurrent BCa. Those are actually subject to a multi center study with 1013 patients.